INVECTYS

ALLO-316 CAR-T Therapy Shows Promise in Renal Cell Carcinoma Trial, but Deaths Reported

• Allogene's ALLO-316 demonstrated a 38% overall response rate in renal cell carcinoma patients at dose level 2 in the TRAVERSE phase 1 trial. • In patients with high CD70 expression, ALLO-316 achieved a confirmed overall response rate of 33%, indicating potential for targeted therapy. • The trial reported a manageable safety profile, with mostly low-grade cytokine release syndrome, but included three on-study patient deaths. • ALLO-316, an off-the-shelf CAR-T therapy, shows potential as a novel treatment for metastatic RCC resistant to multiple therapeutic classes.